Entera Bio Ltd.

ENTX

Healthcare|Biotechnology|IL

$3.14

+0.15 (+5.02%)

DCF Value

$0.14

Tangible Book / Share

$1.89

Graham Number

$0.72

Cash / Share

$1.83

Clinical Trials (6)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT03516773 Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism	Hypoparathyroidism	P2	Completed	20	RCT, Open-label	EB612 (EBP05), NATPARA/NATPAR
NCT02152228 A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism	Hypoparathyroidism	P2	Completed	20	Open-label	EnteraBio's Oral Parathyroid Hormone (1-34)
NCT04003467 A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass	Osteoporosis	P2	Completed	161	RCT, Double-blind	EBP05, Placebo of EBP05
NCT02571140 A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects	Drug Safety and Bioavailability	P1	Completed	30	Open-label	Teriparatide, Oral PTH (1-34)
NCT05965167 Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo	Hypoparathyroidism, Osteoporosis	P1	Completed	45	RCT, Open-label	EBP05, Forteo 0.02 mg, EBP11, EBP22, EBP11-F2, EBP11-F4, EBP11-F1, EBP11-F5
NCT02202603 A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects	Drug Safety	P1	Completed	42	RCT, Double-blind	Teriparatide, Teriparatide, placebo